Page last updated: 2024-11-11
am 694
Description
1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole : A member of the class of indoles that is 1H-indole which is substituted at position 1 by a 5-fluoropentyl group and a position 3 by an o-fluorobenzoyl group. It is a selective agonist for the CB1 cannabinoid receptor; Ki values for the CB1 and CB2 receptors are 0.08 and 1.44 nM, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 9889172 |
| CHEBI ID | 138017 |
| SCHEMBL ID | 16755254 |
| MeSH ID | M0568865 |
Synonyms (28)
| Synonym |
|---|
| [1-(5-fluoropentyl)indol-3-yl]-(2-iodophenyl)methanone |
| am694 |
| am-694 |
| [1-(5-fluoropentyl)-1h-indol-3-yl](2-iodophenyl)methanone |
| 335161-03-0 |
| CHEBI:138017 |
| 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole |
| FT-0661541 |
| 6rk7kn7l1o , |
| am 694 |
| unii-6rk7kn7l1o |
| dea no. 7694 |
| CCG-208750 |
| SCHEMBL16755254 |
| AKOS025149518 |
| LFFIIZFINPPEMC-UHFFFAOYSA-N |
| 1-[(5-fluoropentyl)-1h-indol-3-yl]-(2-iodophenyl)methanone |
| 1-5-fluoropentyl)-3-(2-iodobenzoyl)indole |
| 1-((5-fluoropentyl)-1h-indol-3-yl)-(2-iodophenyl)methanone |
| j2.929.919f , |
| methanone, (1-(5-fluoropentyl)-1h-indol-3-yl)(2-iodophenyl)- |
| DTXSID30187156 |
| am-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)-indole) |
| am-694; 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole |
| am-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) 1.0 mg/ml in acetonitrile |
| am-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) 0.1 mg/ml in acetonitrile |
| BCP21329 |
| Q4652501 |
Roles (1)
| Role | Description |
|---|
| cannabinoid receptor agonist | An agonist that binds to and activates cannabinoid receptors. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
| Class | Description |
|---|
| indoles | Any compound containing an indole skeleton. |
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| organoiodine compound | An organoiodine compound is a compound containing at least one carbon-iodine bond. |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| synthetic cannabinoid | A class of cannabinoid that consists of synthetic analogs of the naturally occuring cannabinoids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 47.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 47.03 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.51 (4.65) | | Search Engine Demand Index | 69.20 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (14.29%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |